(Q50143115)

25 February 2018

title

A FRAX® model for the assessment of fracture probability in Belgium. (English)

1 reference

25 February 2018

0 references

1 reference

H Johansson

1

1 reference

25 February 2018

J A Kanis

2

1 reference

25 February 2018

E V McCloskey

3

1 reference

25 February 2018

A Odén

4

1 reference

25 February 2018

J-P Devogelaer

5

1 reference

25 February 2018

J-M Kaufman

6

1 reference

25 February 2018

A Neuprez

7

1 reference

25 February 2018

M Hiligsmann

8

1 reference

25 February 2018

O Bruyere

9

1 reference

25 February 2018

J-Y Reginster

10

1 reference

25 February 2018

language of work or name

English

0 references

publication date

30 March 2010

1 reference

25 February 2018

Osteoporosis International

published in

1 reference

25 February 2018

volume

22

1 reference

25 February 2018

issue

2

1 reference

25 February 2018

page(s)

453-461

1 reference

25 February 2018

https://scigraph.springernature.com/pub.10.1007/s00198-010-1218-1

exact match

0 references

cites work

Updated data on proximal femur bone mineral levels of US adults

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

A reference standard for the description of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

FRAX and the assessment of fracture probability in men and women from the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

The burden of osteoporotic fractures: a method for setting intervention thresholds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Patient assessment using standardized bone mineral density values and a national reference database: implementing uniform thresholds for the reimbursement of osteoporosis treatments in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Dual energy x-ray absorptiometry-based assessment of male patients using standardized bone density values and a national reference database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Body mass index as a predictor of fracture risk: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

FRAX and its applications to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

BMD, clinical risk factors and their combination for hip fracture prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

An assessment tool for predicting fracture risk in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Prediction of fracture in nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

An approach to identifying osteopenic women at increased short-term risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Methodology for identifying patients at high risk for osteoporotic fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Can historical and functional risk factors be used to predict fractures in community-dwelling older adults? development and validation of a clinical tool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Utility of medical and drug history in fracture risk prediction among men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Risk of hip fracture in disabled community-living older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Guidelines for diagnosis and management of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

International variations in hip fracture probabilities: implications for risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Bone Mineral Density Testing in Healthy Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1218-1

Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women.

21 January 2018

1 reference

12 December 2020

Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks

1 reference

12 December 2020

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

12 December 2020

Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis

1 reference

12 December 2020

Added value of bone mineral density in hip fracture risk scores

1 reference

12 December 2020

The diagnosis of osteoporosis

1 reference

12 December 2020

Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study

1 reference

12 December 2020

Use of Clinical Risk Factors in Elderly Women with Low Bone Mineral Density to Identify Women at Higher Risk of Hip Fracture: The EPIDOS Prospective Study

1 reference

12 December 2020

Optimization of BMD measurements to identify high risk groups for treatment--a test analysis

1 reference

12 December 2020

Risk factors for perimenopausal distal forearm fracture

1 reference

12 December 2020

Modeling fracture risk using bone density, age, and years since menopause

1 reference

12 December 2020

Evaluation of a Hip Fracture Risk Score for Assessing Elderly Women: The Melton Osteoporotic Fracture (MOF) Study

1 reference

12 December 2020

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

1 reference

12 December 2020

Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study

1 reference

12 December 2020

10.1007/S00198-010-1218-1

Identifiers

DOI

1 reference

25 February 2018

PubMed ID

20352409

1 reference

25 February 2018